Thus, the combination of oxaliplatin with strategies designed to inhibit CCN2/MAPK/Erk signaling could provide a promising approach to ameliorating HCC progression, especially oxaliplatin resistance. Here, CCN2 is linked to hepatocellular carcinoma.